Tandem Diabetes Care, Inc. (TNDM)
- Previous Close
49.57 - Open
49.04 - Bid 48.80 x 200
- Ask 48.89 x 400
- Day's Range
48.64 - 50.22 - 52 Week Range
13.82 - 53.69 - Volume
1,052,572 - Avg. Volume
1,546,412 - Market Cap (intraday)
3.155B - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-2.16 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
50.93
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
www.tandemdiabetes.comRecent News: TNDM
Performance Overview: TNDM
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TNDM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TNDM
Valuation Measures
Market Cap
3.16B
Enterprise Value
3.16B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.13
Price/Book (mrq)
12.98
Enterprise Value/Revenue
4.11
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.37%
Return on Assets (ttm)
-9.70%
Return on Equity (ttm)
-48.63%
Revenue (ttm)
770.01M
Net Income Avi to Common (ttm)
-141.45M
Diluted EPS (ttm)
-2.16
Balance Sheet and Cash Flow
Total Cash (mrq)
467.81M
Total Debt/Equity (mrq)
196.47%
Levered Free Cash Flow (ttm)
-44.57M
Research Analysis: TNDM
Company Insights: TNDM
TNDM does not have Company Insights
Research Reports: TNDM
Tandem Earnings: Launch of Mobi and CGM Integrations Bodes Well for 2024
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
RatingPrice TargetRaising target price to $32.00
TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $32.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $31.00
TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $31.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $30.00
TANDEM DIABETES CARE INC has an Investment Rating of SELL; a target price of $30.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target